¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå ±Ô¸ð Á¶»ç : Á¦Ç°/¼Ö·ç¼Ç, ±â¼ú, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº° ¿¹Ãø(2022-2032³â)
Global 3D Bioprinting in Medical Market Size study, by Products and Solutions by Technology, by Application, by End User and Regional Forecasts 2022-2032
»óǰÄÚµå
:
1477059
¸®¼Ä¡»ç
:
Bizwit Research & Consulting LLP
¹ßÇàÀÏ
:
2024³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 200 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀåÀº 2023³â ¾à 12¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024-2032³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 15.5% ÀÌ»óÀÇ °ßÁ¶ÇÑ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃÀº Á¶Á÷°øÇÐ ¹× Àç»ýÀÇ·á¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ Á¢±Ù¹ýÀÔ´Ï´Ù. »ýü Àç·á, ¼¼Æ÷, ¼ºÀå ÀÎÀÚ¸¦ Ãþº°·Î Á¤È®ÇÏ°Ô ÁõÂøÇÏ¿© ¿ø·¡ Á¶Á÷°ú Àå±âÀÇ º¹ÀâÇÑ ±¸Á¶¿Í ±â´ÉÀ» ¸ð¹æÇÑ 3Â÷¿ø ±¸Á¶¸¦ »ý¼ºÇÏ´Â ±â¼úÀÔ´Ï´Ù. ÀÌ ÃÖ÷´Ü ±â¼úÀº Àå±â À̽Ä, ¾à¹° ½ºÅ©¸®´×, Áúº´ ¸ðµ¨¸µ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á µî ´Ù¾çÇÑ ÀÀ¿ë ºÐ¾ß¿¡ Å« ±â´ë¸¦ ¸ðÀ¸°í ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀåÀÇ Æ®·»µå´Â ÀÌÁ¾ ¼ººÐÀÇ º¹ÀâÇÑ Á¶Á÷ ±¸Á¶¸¦ »ý¼ºÇÒ ¼ö ÀÖ´Â ´ÙÀç·á, ´Ù¼¼Æ÷ ÇÁ¸°ÆÃÀ¸·Î ÇâÇϰí ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ ¼¼Æ÷ À¯Çü°ú »ýü Àç·á¸¦ ÇÁ¸°ÆÃ °øÁ¤¿¡ ÅëÇÕÇÔÀ¸·Î½á ¿¬±¸ÀÚµéÀº ¿ø·¡ÀÇ Á¶Á÷°ú ±â°ü¿¡¼ ¹ß°ßµÇ´Â ´Ù¾çÇÑ ¹Ì¼¼ ȯ°æÀ» ¸ð¹æÇÏ¿© ±¸Á¶¹°ÀÇ ±â´É¼º°ú »ý¹°ÇÐÀû °ü·Ã¼ºÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù.
¼¼°è ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀåÀº ¸î °¡Áö ÁÖ¿ä ¿äÀο¡ ÈûÀÔ¾î °·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¸¸¼º ÁúȯÀÇ È®»ê°ú ´õºÒ¾î Áúº´ ÁøÇàÀ» ¿¬±¸Çϰí Ç¥Àû Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇÑ º¸´Ù Á¤È®ÇÑ ¸ðµ¨¸µÀÌ Àý½ÇÈ÷ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â Áúº´ ¸ðµ¨¸µ ¹× ¾à¹° Å×½ºÆ® ¿ëµµ¿¡¼ 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Advanced Regenerative Manufacturing Institute(ARMI)´Â ÁÖ¿ä Á¦Á¶¾÷ü, ´ëÇÐ, ºñ¿µ¸® ´Üü ¹× ¿¬¹æ Á¤ºÎ·ÎºÎÅÍ 3¾ï ´Þ·¯ ÀÌ»óÀÇ ¸·´ëÇÑ ÅõÀÚ¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ ÀÚ±ÝÀº Àΰø Á¶Á÷ ¹× Àå±âÀÇ È®Àå °¡´ÉÇÑ Á¦Á¶ °øÁ¤ °³¹ßÀ» ÃËÁøÇϱâ À§ÇÑ °ÍÀ¸·Î, 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ±â¼ú ¹ßÀü¿¡ ´ëÇÑ ¾÷°èÀÇ ³ë·ÂÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼¼°è ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀåÀº 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ±â¼úÀÇ ¹ßÀü°ú ÀÇ·á ¿¬±¸ ¹× °³¹ß Ȱµ¿¿¡ ´ëÇÑ ÁöÃâ Áõ°¡¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª Á¶Á÷ °øÇÐÀÇ º¹À⼺°ú 3D ¹ÙÀÌ¿À ÇÁ¸°ÆÃ ½Ã½ºÅÛ°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀº 2022³âºÎÅÍ 2032³â±îÁö ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä« ¹× ±âŸ ¼¼°è Áö¿ªÀ̸ç, 2023³â À¯·´ÀÌ °¡Àå ±Ô¸ð°¡ Å« Áö¿ª ½ÃÀåÀ¸·Î ºÎ»óÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀº ÀÇ·á¿ë 3D ¹ÙÀÌ¿À ÇÁ¸°ÆÃ Á¦Á¶ ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² 3D Systems Corporation ¹× Organovo Holdings, Inc.¿Í °°Àº ÁÖ¿ä ±â¾÷ÀÇ Á¸Àç¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀº ÀÇ·á ÀÎÇÁ¶ó°¡ Àß ±¸ÃàµÇ¾î ÀÖ°í ¿¬±¸°³¹ß(R&D)¿¡ ¸¹Àº ÅõÀÚ°¡ ÀÌ·ç¾îÁö°í ÀÖ¾î 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ°ú °°Àº ÷´Ü ±â¼úÀÇ ¹ßÀü°ú äÅÿ¡ µµ¿òÀÌ µÇ´Â ȯ°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ºÐ¾ßÀÇ Çõ½Å°ú °³Ã´ÀÇ Áß½ÉÁö·Î ÀÚ¸®¸Å±èÇÏ¸ç ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ º¸°í¼¿¡ Æ÷ÇÔµÈ ÁÖ¿ä ½ÃÀå ±â¾÷Àº ´ÙÀ½°ú °°½À´Ï´Ù.
- 3D Systems Corporation
- Desktop Metal, Inc.
- Organovo Holdings, Inc.
- Cyfuse Biomedical K.K
- Medprin Biotech GmbH
- Advanced Solutions, Inc.
- CollPlant Biotechnologies Ltd
- REGEMAT 3D S.L
- The Bio Convergence Company
- Shining 3D
¸ñÂ÷
Á¦1Àå ¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå Á¤ÀÇ¿Í Á¶»çÀÇ ÀüÁ¦Á¶°Ç
- Á¶»ç ¸ñÀû
- ½ÃÀåÀÇ Á¤ÀÇ
- Á¶»çÀÇ ÀüÁ¦Á¶°Ç
- Æ÷ÇÔ°ú Á¦¿Ü
- Á¦ÇÑ »çÇ×
- °ø±ÞÃø ºÐ¼®
- °¡¿ë¼º
- ÀÎÇÁ¶ó
- ±ÔÁ¦ ȯ°æ
- ½ÃÀå °æÀï
- °æÁ¦¼º(¼ÒºñÀÚ ½ÃÁ¡)
- ¼ö¿äÃø ºÐ¼®
- ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
- ±â¼ú Áøº¸
- ģȯ°æ
- ¼ÒºñÀÚ Àǽİú ¼ö¿ë
- Á¶»ç ¹æ¹ý
- Á¶»ç ´ë»ó³âµµ
- ÅëÈ È¯»êÀ²
Á¦2Àå ÁÖ¿ä ¿ä¾à
- ¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå ±Ô¸ð£¦¿¹Ãø(2022³â-2032³â)
- Áö¿ªº° °³¿ä
- ºÎ¹®º° °³¿ä
- Á¦Ç°¡¤¼Ö·ç¼Çº°
- ±â¼úº°
- ¿ëµµº°
- ÃÖÁ¾»ç¿ëÀÚº°
- ÁÖ¿ä µ¿Çâ
- °æ±âÈÄÅðÀÇ ¿µÇâ
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È
Á¦3Àå ¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
- ½ÃÀå ±âȸ
Á¦4Àå ¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ¹ÙÀ̾îÀÇ ±³¼··Â
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷°£ °æÀï °ü°è
- Porter's Five Forces ¸ðµ¨¿¡ ´ëÇÑ ¹Ì·¡Àû Á¢±Ù
- Porter's Five ForcesÀÇ ¿µÇ⠺м®
- PESTEL ºÐ¼®
- Á¤Ä¡
- °æÁ¦
- »çȸ
- 񃬣
- ȯ°æ
- ¹ý·ü
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- ÆÄ±«Àû µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ °ßÇØ
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È
Á¦5Àå ¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå : Á¦Ç°¡¤¼Ö·ç¼Çº° ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2022³â-2032³â
- ¹ÙÀÌ¿ÀÇÁ¸°ÅÍ
- ¼Ò¸ðǰ ¹× ºÎ¼Óǰ
- ¼ÒÇÁÆ®¿þ¾î ¹× ¼ºñ½º
Á¦6Àå ¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ±â¼úº°, 2022³â-2032³â
- ¾ÐÃâ ±â¹Ý ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ
- À×Å©Á¬ ±â¹Ý ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ
- ·¹ÀÌÀú Áö¿ø ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ
- ±âŸ
Á¦7Àå ¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå ±Ô¸ð¡¤¿ëµµº° ¿¹Ãø, 2022³â-2032³â
- Á¶Á÷°øÇÐ ¹× Àç»ýÀÇ·á
- Drug Discovery & Development
- ±âŸ
Á¦8Àå ¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2022³â-2032³â
- ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ¹× Á¦¾à ±â¾÷
- Çмú±â°ü ¹× ¿¬±¸±â°ü
- ±âŸ
Á¦9Àå ¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå ±Ô¸ð, Áö¿ªº° ¿¹Ãø, 2022³â-2032³â
- ºÏ¹ÌÀÇ ÀÇ·á¿ëÀÇ 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ¹Ì±¹
- Á¦Ç° ¹× ¼Ö·ç¼Çº°, ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, 2022³â-2032³â
- ±â¼ú ºÐ¼® : ½ÃÀå ±Ô¸ð£¦¿¹Ãø, 2022³â-2032³â
- ¿ëµµ ºÐ¼® : ½ÃÀå ±Ô¸ð£¦¿¹Ãø, 2022³â-2032³â
- ÃÖÁ¾»ç¿ëÀÚ ºÐ¼® : ½ÃÀå ±Ô¸ð£¦¿¹Ãø, 2022³â-2032³â
- ij³ª´ÙÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- À¯·´ÀÇ 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ¿µ±¹ÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- µ¶ÀÏÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ÇÁ¶û½ºÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ½ºÆäÀÎÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ÀÌÅ»¸®¾ÆÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ±âŸ À¯·´ 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- Áß±¹ÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ÀεµÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ÀϺ»ÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- È£ÁÖÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- Çѱ¹ÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÀÇ·á¿ëÀÇ 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ºê¶óÁúÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ¸ß½ÃÄÚÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÇ·á¿ëÀÇ 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- »ç¿ìµð¾Æ¶óºñ¾ÆÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹ÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå
Á¦10Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ °³¿ä
- 3D Systems Corporation
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
- Á¦Ç° °³¿ä
- ½ÃÀå Àü·«
- Desktop Metal, Inc.
- Organovo Holdings, Inc.
- Cyfuse Biomedical K.K
- Medprin Biotech GmbH
- Advanced Solutions, Inc.
- CollPlant Biotechnologies Ltd
- REGEMAT 3D S.L
- The Bio Convergence Company
- Shining 3D
Á¦11Àå Á¶»ç °úÁ¤
- Á¶»ç °úÁ¤
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- ºÐ¼®
- ½ÃÀå ÃßÁ¤
- °ËÁõ
- ÃâÆÇ
- Á¶»ç ¼Ó¼º
LSH
¿µ¹® ¸ñÂ÷
Global 3D Bioprinting in Medical Market is valued approximately at USD 1.27 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 15.5% over the forecast period 2024-2032. 3D bioprinting in the medical field represents a revolutionary approach to tissue engineering and regenerative medicine. It involves the precise layer-by-layer deposition of biomaterials, cells, and growth factors to create three-dimensional structures that mimic the complex architecture and functionality of native tissues and organs. This cutting-edge technology holds immense promise for a wide range of applications, including organ transplantation, drug screening, disease modeling, and personalized medicine. Global 3D Bioprinting in Medical Market trends towards multi-material and multi-cellular printing which allows the creation of complex tissue structures with heterogeneous compositions. By incorporating different cell types and biomaterials into the printing process, researchers can mimic the diverse microenvironments found in native tissues and organs, enhancing the functionality and biological relevance of the constructs.
The Global 3D Bioprinting in medical Market is experiencing robust growth, propelled by several key factors. The escalating prevalence of chronic diseases, coupled with the pressing need for more accurate models to study disease progression and develop targeted therapies. This is driving the demand for 3D bioprinting in disease modeling and drug testing applications. For instance, significant investments, exceeding USD 300 million, have been granted to Advanced Regenerative Manufacturing Institute (ARMI) by leading manufacturers, universities, nonprofit organizations, and the federal government. This funding aims to foster the development of scalable manufacturing processes for engineered tissues and organs, reflecting the industry's commitment to advancing 3D bioprinting technologies. Furthermore, Global 3D Bioprinting in medical Market is driven by rising advancements in 3D bioprinting technologies and rising spending in medical research and development activities. However, complexity of tissue engineering and high costs associated with 3D bioprinting systems is expected to stifle the market growth between 2022 and 2032.
The key regions considered for the global 3D Bioprinting in Medical market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, Europe was the largest regional market in the market place. The regional market growth is propelled by the presence of key players such as 3D Systems Corporation and Organovo Holdings, Inc., alongside advancements in the manufacturing technology of 3D bioprinting for medical applications. Furthermore, the region has well-established healthcare infrastructure and substantial investment in research and development (R&D), fostering an environment conducive to the advancement and adoption of cutting-edge technologies like 3D bioprinting. These factors collectively drive market growth, positioning the region as a hub for innovation and development in the field of medical 3D bioprinting. The market in Asia Pacific, on the other hand, is expected to grow at the fastest rate over the forecast period.
Major market player included in this report are:
- 3D Systems Corporation
- Desktop Metal, Inc.
- Organovo Holdings, Inc.
- Cyfuse Biomedical K.K
- Medprin Biotech GmbH
- Advanced Solutions, Inc.
- CollPlant Biotechnologies Ltd
- REGEMAT 3D S.L
- The Bio Convergence Company
- Shining 3D
The detailed segments and sub-segment of the market are explained below:
By Products and Solution
- Bioprinters
- Consumables and accessories
- Software and services
By Technology
- Extrusion based bioprinting
- Inkjet based bioprinting
- Laser assisted bioprinting
- Others
By Application
- Tissue engineering and regenerative medicine
- Drug discovery and development
- Others
By End User
- Biotechnology and pharmaceutical companies
- Academic and research institutes
- Others
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- RoMEA
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global 3D Bioprinting in Medical Market Definition and Research Assumptions
- 1.1. Research Objective
- 1.2. Market Definition
- 1.3. Research Assumptions
- 1.3.1. Inclusion & Exclusion
- 1.3.2. Limitations
- 1.3.3. Supply Side Analysis
- 1.3.3.1. Availability
- 1.3.3.2. Infrastructure
- 1.3.3.3. Regulatory Environment
- 1.3.3.4. Market Competition
- 1.3.3.5. Economic Viability (Consumer's Perspective)
- 1.3.4. Demand Side Analysis
- 1.3.4.1. Regulatory frameworks
- 1.3.4.2. Technological Advancements
- 1.3.4.3. Environmental Considerations
- 1.3.4.4. Consumer Awareness & Acceptance
- 1.4. Estimation Methodology
- 1.5. Years Considered for the Study
- 1.6. Currency Conversion Rates
Chapter 2. Executive Summary
- 2.1. Global 3D Bioprinting in Medical Market Size & Forecast (2022- 2032)
- 2.2. Regional Summary
- 2.3. Segmental Summary
- 2.3.1. By Products and Solutions
- 2.3.2. By Technology
- 2.3.3. By Application
- 2.3.4. By End User
- 2.4. Key Trends
- 2.5. Recession Impact
- 2.6. Analyst Recommendation & Conclusion
Chapter 3. Global 3D Bioprinting in Medical Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Challenges
- 3.3. Market Opportunities
Chapter 4. Global 3D Bioprinting in Medical Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top investment opportunity
- 4.4. Top winning strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global 3D Bioprinting in Medical Market Size & Forecasts by Products and Solutions 2022-2032
- 5.1. Bioprinters
- 5.2. Consumables and accessories
- 5.3. Software and services
Chapter 6. Global 3D Bioprinting in Medical Market Size & Forecasts by Technology 2022-2032
- 6.1. Extrusion based bioprinting
- 6.2. Inkjet based bioprinting
- 6.3. Laser assisted bioprinting
- 6.4. Others
Chapter 7. Global 3D Bioprinting in Medical Market Size & Forecasts by Application 2022-2032
- 7.1. Tissue engineering and regenerative medicine
- 7.2. Drug discovery and development
- 7.3. Others
Chapter 8. Global 3D Bioprinting in Medical Market Size & Forecasts by End User 2022-2032
- 8.1. Biotechnology and pharmaceutical companies
- 8.2. Academic and research institutes
- 8.3. Others
Chapter 9. Global 3D Bioprinting in Medical Market Size & Forecasts by Region 2022-2032
- 9.1. North America 3D Bioprinting in Medical Market
- 9.1.1. U.S. 3D Bioprinting in Medical Market
- 9.1.1.1. Products and Solution breakdown size & forecasts, 2022-2032
- 9.1.1.2. Technology breakdown size & forecasts, 2022-2032
- 9.1.1.3. Application breakdown size & forecasts, 2022-2032
- 9.1.1.4. End User breakdown size & forecasts, 2022-2032
- 9.1.2. Canada 3D Bioprinting in Medical Market
- 9.2. Europe 3D Bioprinting in Medical Market
- 9.2.1. U.K. 3D Bioprinting in Medical Market
- 9.2.2. Germany 3D Bioprinting in Medical Market
- 9.2.3. France 3D Bioprinting in Medical Market
- 9.2.4. Spain 3D Bioprinting in Medical Market
- 9.2.5. Italy 3D Bioprinting in Medical Market
- 9.2.6. Rest of Europe 3D Bioprinting in Medical Market
- 9.3. Asia-Pacific 3D Bioprinting in Medical Market
- 9.3.1. China 3D Bioprinting in Medical Market
- 9.3.2. India 3D Bioprinting in Medical Market
- 9.3.3. Japan 3D Bioprinting in Medical Market
- 9.3.4. Australia 3D Bioprinting in Medical Market
- 9.3.5. South Korea 3D Bioprinting in Medical Market
- 9.3.6. Rest of Asia Pacific 3D Bioprinting in Medical Market
- 9.4. Latin America 3D Bioprinting in Medical Market
- 9.4.1. Brazil 3D Bioprinting in Medical Market
- 9.4.2. Mexico 3D Bioprinting in Medical Market
- 9.4.3. Rest of Latin America 3D Bioprinting in Medical Market
- 9.5. Middle East & Africa 3D Bioprinting in Medical Market
- 9.5.1. Saudi Arabia 3D Bioprinting in Medical Market
- 9.5.2. South Africa 3D Bioprinting in Medical Market
- 9.5.3. Rest of Middle East & Africa 3D Bioprinting in Medical Market
Chapter 10. Competitive Intelligence
- 10.1. Key Company SWOT Analysis
- 10.2. Top Market Strategies
- 10.3. Company Profiles
- 10.3.1. 3D Systems Corporation
- 10.3.1.1. Key Information
- 10.3.1.2. Overview
- 10.3.1.3. Financial (Subject to Data Availability)
- 10.3.1.4. Product Summary
- 10.3.1.5. Market Strategies
- 10.3.2. Desktop Metal, Inc.
- 10.3.3. Organovo Holdings, Inc.
- 10.3.4. Cyfuse Biomedical K.K
- 10.3.5. Medprin Biotech GmbH
- 10.3.6. Advanced Solutions, Inc.
- 10.3.7. CollPlant Biotechnologies Ltd
- 10.3.8. REGEMAT 3D S.L
- 10.3.9. The Bio Convergence Company
- 10.3.10. Shining 3D
Chapter 11. Research Process
- 11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
- 11.2. Research Attributes
°ü·ÃÀÚ·á